Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.

ABSTRACT: P53 mutation (TP53m) is a common intrinsic factor involved in relapsed or refractory (R/R) B cell malignancies that associates with treatment resistance. As a novel immunotherapy, CAR-T has been increasingly applied in TP53m B cell malignancies, yet whether it can overcome the poor outcome of the TP53m population is controversial. We searched MEDLINE and EMBASE to identify population-based cohort studies that evaluated the CAR-T treatment outcomes between wild type and TP53m patients in B cell malignancies. Meta-analysis on their complete response (CR), partial response (PR), overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) was carried out and pooled risk ratios (RR) or hazard ratios (HR) were estimated. A total of 10 eligible studies reporting 848 pat

SUBMITTER: Qi W 

PROVIDER: S-EPMC12454170 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature